Aravax, a company focused on developing safe, effective, and precisely targeted treatments for food allergies, announced that it has launched a UK branch located at the Oxford Science Park. This expansion supports the company’s mission to become a leading global player in providing innovative allergy treatments.
The UK operations will drive the development of manufacturing processes for Aravax’s peptide-based therapies, supporting their advanced immunotherapies like PVX108, which is nearing Phase 3. Aravax plans to invest around USD 10 million in manufacturing development over the next two years. Having a base in the UK also strengthens Aravax’s global footprint for business growth, while the company’s main office in Australia will continue to oversee clinical development and other key activities.
Dr. Paul Laidler, Vice President of Pharmaceutical Development at Aravax (UK), stated, “Having operations in Oxford provides excellent access to top expertise in the UK and Europe for sterile, peptide-based product manufacturing, as well as the global life sciences ecosystem.”
Dr. Pascal Hickey, CEO of Aravax, expressed, “Our goal is to become a world leader in food allergy treatment by developing safe and easy-to-use immunotherapies that meet the urgent need for improved solutions. Achieving this requires a global outlook and diverse capabilities, and establishing our Oxford operations is a crucial step forward for us. The company has made remarkable progress with its groundbreaking technology, which holds the potential to significantly improve treatment options for people suffering from food allergies.”
Earlier this year, Aravax raised approximately USD 42 million in Series B funding to accelerate the development of PVX108, their leading candidate for treating peanut allergies. The Phase 2 clinical trials in Australia and the USA are now fully enrolled, with results expected in the first half of 2026.